Danish drugmaker Novo Nordisk said it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions from Nov. 11-13.
https://www.pharmalive.com/wp-content/uploads/2023/09/Novo-Nordisk-logo.jpg500656Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-11-07 08:46:512023-11-07 09:44:27Novo Nordisk to present new data from weight-loss, diabetes trials
